These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1796038)

  • 21. Targeting naproxen to non-parenchymal liver cells protects against endotoxin induced liver damage.
    Lebbe C; Reichen J; Wartna E; Sägesser H; Poelstra K; Meijer DK
    J Drug Target; 1997; 4(5):303-10. PubMed ID: 9169987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP; Vree JB; Guelen PJ
    Biopharm Drug Dispos; 1993 Aug; 14(6):491-502. PubMed ID: 8218967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic studies of naproxen amides of some amino acid esters with promising colorectal cancer chemopreventive activity.
    Aboul-Fadl T; Al-Hamad SS; Fouad EA
    Bioorg Chem; 2018 Feb; 76():370-379. PubMed ID: 29241109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselective binding properties of naproxen glucuronide diastereomers to proteins.
    Bischer A; Zia-Amirhosseini P; Iwaki M; McDonagh AF; Benet LZ
    J Pharmacokinet Biopharm; 1995 Aug; 23(4):379-95. PubMed ID: 8882746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
    Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereoselective disposition of naproxen glucuronide in the rat.
    Iwaki M; Bischer A; Nguyen AC; McDonagh AF; Benet LZ
    Drug Metab Dispos; 1995 Oct; 23(10):1099-103. PubMed ID: 8654198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged naproxen joint residence time after intra-articular injection of lipophilic solutions comprising a naproxen glycolamide ester prodrug in the rat.
    Thing M; Lu Y; Agårdh L; Larsen C; Ostergaard J; He W; Wu W; Larsen F; Larsen SW
    Int J Pharm; 2013 Jul; 451(1-2):34-40. PubMed ID: 23624087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles.
    Olsen J; Bjørnsdottir I; Tjørnelund J; Honoré Hansen S
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):7-15. PubMed ID: 12062660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of aminoglycosides on glomerular permeability, tubular reabsorption, and intracellular catabolism of the cationic low-molecular-weight protein lysozyme.
    Cojocel C; Dociu N; Maita K; Sleight SD; Hook JB
    Toxicol Appl Pharmacol; 1983 Mar; 68(1):96-109. PubMed ID: 6845378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.
    Prakash J; van Loenen-Weemaes AM; Haas M; Proost JH; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
    Drug Metab Dispos; 2005 May; 33(5):683-8. PubMed ID: 15673598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative aspects of the uptake and degradation of lysozyme in the rat kidney in vivo.
    Hysing J; Tolleshaug H
    Biochim Biophys Acta; 1986 Jun; 887(1):42-50. PubMed ID: 3708010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney.
    Nagai J; Katsube T; Murakami T; Takano M
    J Pharm Pharmacol; 2002 Nov; 54(11):1491-6. PubMed ID: 12495551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
    Wang-Smith L; Fort J; Zhang Y; Sostek M
    J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis.
    Favari L; Castañeda-Hernández G; Hoyo-Vadillo C
    Arzneimittelforschung; 1993 Jun; 43(6):675-9. PubMed ID: 8352821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats.
    Iwakawa S; Spahn H; Benet LZ; Lin ET
    Drug Metab Dispos; 1991; 19(5):853-7. PubMed ID: 1686227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of low-molecular weight protein (LMWP) lysozyme-curcumin conjugates for kidney drug targeting.
    Wang Y; Sun Y; Wang H; Liu P; Peng W; Duan Y
    J Biomater Sci Polym Ed; 2013; 24(11):1360-7. PubMed ID: 23796036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of naproxen and its metabolite O-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatography.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
    J Chromatogr; 1992 Jul; 578(2):239-49. PubMed ID: 1400803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery.
    Sheha M
    Arch Pharm Res; 2012 Mar; 35(3):523-30. PubMed ID: 22477200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.